Comparison of NEDA3 at one year between alemtuzumab and natalizumab in treatment-naive relapsing-remitting multiple sclerosis patients.

被引：0
|
作者：
Gomez, A. [1 ]
Rodriguez, F. [1 ]
Chico, J. L. [1 ]
Sanchez Sanchez, A. [1 ]
Natera, E. [1 ]
Sainz de la Maza, S. [1 ]
Villar Guimerans, L. M. [2 ]
Buisan Catevilla, F. J. [1 ]
Costa-Frossard Franca, L. [1 ]
Masjuan, J. [1 ]
Monreal, E. [1 ]
机构：
[1] Hosp Ramon & Cajal, Neurol, Madrid, Spain
[2] Hosp Univ Ramon y Cajal, Inmunol, Madrid, Spain
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2019年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO1245
引用
收藏
页码：493 / 493
页数：1
相关论文
共 50 条
  • [1] Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients
    Fox, Edward J.
    Wynn, Daniel
    Coles, Alasdair J.
    Palmer, Jeffrey
    Margolin, David H.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2016, 363 : 188 - 194
  • [2] Alemtuzumab reduces disease activity in treatment-naive patients with highly active relapsing-remitting multiple sclerosis
    Krieger, S.
    Lubetzki, C.
    Palmer, J.
    Margolin, D. H.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 106 - 107
  • [3] Clinical predictors of disability in treatment-naive relapsing-remitting multiple sclerosis patients
    Ivaniuk, A.
    Solodovnikova, I.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 921 - 921
  • [4] Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
    Hersh, Carrie M.
    Cohen, Jeffrey A.
    IMMUNOTHERAPY, 2014, 6 (03) : 249 - 259
  • [5] Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Fox, Edward J.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1789 - 1797
  • [6] Immune-cell BDNF expression in treatment-naive relapsing-remitting multiple sclerosis patients and following one year of immunomodulation therapy
    Kalinowska-Lyszczarz, Alicja
    Pawlak, Mikolaj A.
    Wyciszkiewicz, Aleksandra
    Osztynowicz, Krystyna
    Kozubski, Wojciech
    Michalak, Slawomir
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2018, 52 (04) : 483 - 489
  • [7] Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
    Rodriguez de Castro, Belen
    Martinez-Mugica Barbosa, Cristina
    Ayastuy Ruiz, Aitor
    Fernandez Gonzalez, Beatriz
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (02) : 112 - 114
  • [8] Autoimmunity in patients treated with alemtuzumab for relapsing-remitting multiple sclerosis
    Fox, E. J.
    Arnold, D. L.
    Cohen, J.
    Coles, A. J.
    Confavreux, C.
    Hartung, H. -P.
    Havrdova, E.
    Selmaj, K.
    Weiner, H.
    Lake, S. L.
    Margolin, D. H.
    Oyuela, P.
    Panzara, M.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 465 - 466
  • [9] High-Efficacy Therapies for Treatment-Naive Individuals with Relapsing-Remitting Multiple Sclerosis
    Freeman, Leorah
    Longbrake, Erin E.
    Coyle, Patricia K.
    Hendin, Barry
    Vollmer, Timothy
    CNS DRUGS, 2022, 36 (12) : 1285 - 1299
  • [10] Natalizumab reduces apathy in relapsing-remitting multiple sclerosis patients
    Berkovich, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S154 - S155
12345